PL3157548T3 - Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym - Google Patents
Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznymInfo
- Publication number
- PL3157548T3 PL3157548T3 PL15741128T PL15741128T PL3157548T3 PL 3157548 T3 PL3157548 T3 PL 3157548T3 PL 15741128 T PL15741128 T PL 15741128T PL 15741128 T PL15741128 T PL 15741128T PL 3157548 T3 PL3157548 T3 PL 3157548T3
- Authority
- PL
- Poland
- Prior art keywords
- therapy
- factor xii
- xii inhibitor
- neurotraumatic disorder
- neurotraumatic
- Prior art date
Links
- 229940123835 Factor XII inhibitor Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14172910 | 2014-06-18 | ||
| PCT/EP2015/063760 WO2015193457A1 (en) | 2014-06-18 | 2015-06-18 | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
| EP15741128.1A EP3157548B1 (en) | 2014-06-18 | 2015-06-18 | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3157548T3 true PL3157548T3 (pl) | 2022-01-17 |
Family
ID=50972542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15741128T PL3157548T3 (pl) | 2014-06-18 | 2015-06-18 | Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20170114119A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3157548B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7109160B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102513050B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106456778A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015276089B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016029624A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2950988C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3157548T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2886859T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3157548T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015193457A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3157548B1 (en) | 2014-06-18 | 2021-08-04 | CSL Behring GmbH | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
| CA3018375A1 (en) * | 2016-03-30 | 2017-10-05 | Carin Sjolund | Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages |
| KR20180132831A (ko) * | 2016-04-06 | 2018-12-12 | 시에스엘 리미티드 | 죽상동맥경화증의 치료 방법 |
| AU2018382222B2 (en) | 2017-12-15 | 2025-09-04 | Csl Limited | Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease |
| WO2020113084A1 (en) * | 2018-11-28 | 2020-06-04 | Oregon Health & Science University | Therapeutic factor xii antibody |
| EP4333901A4 (en) * | 2021-05-03 | 2025-07-09 | Harvard College | FC FUSION PROTEIN-BASED THERAPEUTIC AGENT FOR THE TREATMENT OF PANCREATITIS |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| AU7793291A (en) | 1990-05-10 | 1991-11-27 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| SG89295A1 (en) | 1991-03-15 | 2002-06-18 | Amgen Inc | Pegylation of polypeptides |
| EP0793504B1 (en) | 1994-12-12 | 2005-06-08 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP1803730A1 (en) | 2000-04-12 | 2007-07-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| ES2558102T3 (es) | 2003-05-06 | 2016-02-02 | Biogen Hemophilia Inc. | Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| UA87458C2 (ru) | 2003-06-12 | 2009-07-27 | Елі Ліллі Енд Компані | Гибридные белки-аналоги glp-1 |
| CN1871252A (zh) | 2003-09-05 | 2006-11-29 | Gtc生物治疗学公司 | 在转基因哺乳动物奶中生产融合蛋白的方法 |
| CA2551916C (en) | 2003-12-31 | 2014-04-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| PL1830924T3 (pl) | 2004-12-23 | 2013-08-30 | Csl Behring Gmbh | Zapobieganie tworzeniu i/lub stabilizacji skrzepu |
| CA2678001C (en) | 2007-02-12 | 2017-07-11 | Stefan Schulte | Therapeutic application of kazal-type serine protease inhibitors |
| WO2011069090A1 (en) * | 2009-12-04 | 2011-06-09 | Alavita Pharmaceuticals, Inc. | Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine |
| KR20200116546A (ko) | 2010-12-17 | 2020-10-12 | 안트로제네시스 코포레이션 | 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료 |
| EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| KR101954052B1 (ko) | 2011-03-09 | 2019-03-06 | 체에스엘 베링 게엠베하 | 인공 표면과의 접촉을 포함하는 의료 시술에 투여하기 위한 인자 ｘｉｉ 억제제 |
| EP2548892A1 (en) * | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
| MX347454B (es) | 2011-07-22 | 2017-04-27 | Csl Ltd | Anticuerpos monoclonales inhibidores anti-factor xii-xiia. |
| JP6190368B2 (ja) | 2011-09-24 | 2017-08-30 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 免疫グロブリンおよびｃ１−阻害剤を用いる組合せ療法 |
| EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| DK2964255T3 (da) | 2013-03-08 | 2021-02-08 | Csl Behring Gmbh | Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI) |
| JP2017501968A (ja) | 2013-06-28 | 2017-01-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法 |
| US9587903B2 (en) | 2014-02-24 | 2017-03-07 | Brian E. Sullivan | Pneumatic launcher system and method |
| EP3157548B1 (en) | 2014-06-18 | 2021-08-04 | CSL Behring GmbH | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
| KR20180132831A (ko) | 2016-04-06 | 2018-12-12 | 시에스엘 리미티드 | 죽상동맥경화증의 치료 방법 |
-
2015
- 2015-06-18 EP EP15741128.1A patent/EP3157548B1/en active Active
- 2015-06-18 CN CN201580032338.8A patent/CN106456778A/zh active Pending
- 2015-06-18 DK DK15741128.1T patent/DK3157548T3/da active
- 2015-06-18 PL PL15741128T patent/PL3157548T3/pl unknown
- 2015-06-18 JP JP2016573808A patent/JP7109160B2/ja active Active
- 2015-06-18 BR BR112016029624A patent/BR112016029624A2/pt not_active Application Discontinuation
- 2015-06-18 US US15/318,550 patent/US20170114119A1/en not_active Abandoned
- 2015-06-18 ES ES15741128T patent/ES2886859T3/es active Active
- 2015-06-18 WO PCT/EP2015/063760 patent/WO2015193457A1/en not_active Ceased
- 2015-06-18 AU AU2015276089A patent/AU2015276089B2/en active Active
- 2015-06-18 KR KR1020177001620A patent/KR102513050B1/ko active Active
- 2015-06-18 CA CA2950988A patent/CA2950988C/en active Active
-
2019
- 2019-10-29 US US16/666,886 patent/US12065481B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200131248A1 (en) | 2020-04-30 |
| AU2015276089A1 (en) | 2017-02-02 |
| WO2015193457A1 (en) | 2015-12-23 |
| EP3157548B1 (en) | 2021-08-04 |
| JP7109160B2 (ja) | 2022-07-29 |
| US12065481B2 (en) | 2024-08-20 |
| KR102513050B1 (ko) | 2023-03-29 |
| ES2886859T3 (es) | 2021-12-21 |
| CA2950988A1 (en) | 2015-12-23 |
| US20170114119A1 (en) | 2017-04-27 |
| JP2017524675A (ja) | 2017-08-31 |
| EP3157548A1 (en) | 2017-04-26 |
| DK3157548T3 (da) | 2021-09-06 |
| KR20170016503A (ko) | 2017-02-13 |
| CA2950988C (en) | 2024-02-06 |
| BR112016029624A2 (pt) | 2017-10-24 |
| CN106456778A (zh) | 2017-02-22 |
| AU2015276089B2 (en) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE070659T2 (hu) | KDM1A inhibitor és annak felhasználása terápiában | |
| SG10202005298RA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| GB2531324B (en) | A stylus | |
| GB201517416D0 (en) | Task-execution in a DBMS using stored procedures | |
| GB201405033D0 (en) | Combination therapy | |
| SG11201607597SA (en) | A stair | |
| GB201409535D0 (en) | Arranging components in a two-dimensional area | |
| PL3165360T3 (pl) | Laminat | |
| PL3230318T3 (pl) | Kombinacje inhibitora immunologicznego punktu kontrolnego | |
| PL3230929T3 (pl) | Udoskonalenia w zliczających urządzeniach | |
| SG11201508893YA (en) | Laminate | |
| PL3157548T3 (pl) | Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym | |
| GB2523128B (en) | Improvements in or relating to a secondary drive unit | |
| GB201322628D0 (en) | A game apparatus | |
| GB201416500D0 (en) | A chair back | |
| IL249240A0 (en) | Combined treatment | |
| GB2526425B (en) | A face guard | |
| PL3739138T3 (pl) | Plac zabaw | |
| TWI561187B (en) | A furniture device | |
| HK1232804A1 (en) | Therapy using a factor xii inhibitor in a neurotraumatic disorder | |
| GB201311986D0 (en) | A training shoe | |
| PH32014001219S1 (en) | A chair | |
| PH32014000923S1 (en) | A chair | |
| AU356454S (en) | A chair | |
| GB201402253D0 (en) | A chair |